Skip to main content

ImmunOs Therapeutics AG is a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer. They have recently announced a Series A financing of CHF 15 million, which was co-led by Pfizer Ventures and BioMedPartners. They plan to use the financing to not only complete the first-in-humans trials, but also to broaden the company’s novel immunotherapy iosH platform with additional preclinical programs that will focus on cancer and auto-immunity.

“It is with great pleasure to see that our early research based on HLA open conformer modulation of immune cells is advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumor microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications.” CSO and co-founder Dr. Osiris Marroquin Belaunzaran said.

Along with the financing, the Board of Directors has been expanded with the addition of Dr. Markus Hosang of BioMedPartners; Dr. Michael Baran of Pfizer Inc.; Dr. Reinhard Ambros, former head Novartis Venture Fund; and Dr. Daniel Vasella, former Chairman and CEO Novartis.

For the full press release, click here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.